Global Malignant Ascites Treatment Market Growth (Status and Outlook) 2025-2031

Global Malignant Ascites Treatment Market Growth (Status and Outlook) 2025-2031

The global Malignant Ascites Treatment market size is predicted to grow from US$ 520 million in 2025 to US$ 696 million in 2031; it is expected to grow at a CAGR of 5.0% from 2025 to 2031.

The most common malignancies associated with the development of ascites include cancers of the colon/rectum, ovary, breast, lung, pancreas, liver and lymphoma. Treatment strategies include paracentesis, diuretics and peritoneovenous shunts and so on.

Global Malignant Ascites Treatment key players include BD, B. Braun, Pfizer, Merit Medical Systems, Pfm Medical Ag, etc. Global top five manufacturers hold a share about 40%. North America is the largest market, with a share about 30%, followed by Europe and Middle East & Africa, both have a share about 60 percent. In terms of product, Paracentesis is the largest segment, with a share over 65%.

LPI (LP Information)' newest research report, the “Malignant Ascites Treatment Industry Forecast” looks at past sales and reviews total world Malignant Ascites Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Malignant Ascites Treatment sales for 2025 through 2031. With Malignant Ascites Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Malignant Ascites Treatment industry.

This Insight Report provides a comprehensive analysis of the global Malignant Ascites Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Malignant Ascites Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Malignant Ascites Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Malignant Ascites Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Malignant Ascites Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Malignant Ascites Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
Paracentesis
Chemotherapy
Surgical Treatment
Others

Segmentation by Application:
Hospitals
Clinics
Homecare
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BD
Pfizer
B. Braun
Merit Medical Systems
Pfm Medical Ag
Medtronic
CMP Pharma
GI Supply (Laborie Medical Technologies)
The Surgical Company Group
Sequana Medical
PharmaCyte Biotech
BioVie
Clover Biopharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.